One of the most exciting aspects of medicine is continuous innovation, scientific exploration, and research into how we can provide enhanced care for our patients. The field of ophthalmology has been on the forefront and recipient of revolutionizing technology, novel medications, premium devices, and innovative surgical techniques. Individually or combined, these advancements have provided patients with better vision and improved treatment options.
At SightMD we are continuously coupling efforts with top-tiered patient-centric industry-leading companies to bring the newest techniques, technologies, and medications to our patients through our Department of Clinical Research. Lead by Dr. Alanna Nattis, she has designed, developed, and exclusively accessed investigational treatment studies for wide-ranging ophthalmic conditions such as severe dry eye, glaucoma, refractive and cataract surgery, and retinal pathologies. Having direct access to FDA clinical trials uniquely provides SightMD with state-of-the-art care for our current and future patients.
We are currently recruiting for several active clinical trials. Please contact us for more information!
Currently enrolling trials:
- Contact lens-related dry eye:
Soft daily-wear contact lenses are the ideal vision choice for many patients, as they can allow for better and unrestricted vision, as well as increased ability to perform daily activities. However, while many people benefit from contact lenses, many also experience discomfort, limiting contact lens wear time and may even result in contact lens discontinuation. This study aims to evaluate if the application of artificial tears will help alleviate contact lens discomfort in daily-wear contact lens users. This is a 2-week, 2 visit study. Each study visit will take approximately 30-45 minutes and participants will be given a stipend for their participation.
- Intraocular implant for treatment of mild-moderate open-angle glaucoma/ocular hypertension:
If your doctor has diagnosed you with open-angle glaucoma/ocular hypertension (high eye pressure), you may qualify for this exciting study evaluating an implant that releases pressure-lowering medication into the eye! This Phase 3 FDA trial is designed to evaluate this impressive new technology, which we feel will change the way glaucoma and elevated eye pressure will be treated in the future. This is a 3-year-long study; participants will be given stipends for their participation.
Soon-to-be enrolling trials:
- Trifocal intraocular lens implant for cataract surgery patients
- Presence of Demodex in dry eye patients
- Corneal cross-linking clinical trial
- Inflammatory dry eye study
- Neurotrophic keratitis study
For inquiries, please contact Head Research Coordinator- Heather McBride: 631-957-2816